Loading stock data…
JNJ
$225.25+1.06 (+0.47%)
Market OpenUpdated 9:37 AM EDT
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $224.20. The stock is currently 11% below its 52-week high of $251.71, remaining 9.3% above its 200-day moving average. Technical signals show oversold RSI of 27 and bearish MACD signal, explaining why JNJ maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 27) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
UNHPFEABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$225.25
Potential Upside
14.9%
Whystock Fair Value$258.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Buy
Mean target$252.42+12.1%
Range$155.00 – $285.00
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$544.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
237.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.79%
Volume
Today's trading volume
366,706
Recent News
Trump Administration Targets Dismantling of Already-Weakened DEI
(Bloomberg) -- After a remarkably successful effort to extinguish diversity, equity and inclusion programs at US employers, federal officials are stepping up their push against corporate America’s remaining DEI initiatives.Most Read from BloombergBeijing Tells China Firms to Ignore US Sanctions on RefinersFormer NYC Mayor Giuliani in Critical Condition, Trump SaysSupertanker Appears to Have Crossed the Strait of HormuzWorld’s Largest Container Carrier Plans Route Avoiding HormuzChina’s Unprecede
A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss
You retired with about $2 million saved. The mortgage is gone, Social Security covers the basics, and the brokerage statement looks healthy enough that you finally stopped checking it daily. Somewhere along the way, you parked a big slice of the portfolio in a high-yield savings account paying north of 4% because, frankly, why take ... A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss
Factbox-Global drugmakers rush to boost US presence as tariff threat looms
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut
Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
Jim Cramer Believes Competitors Might Hurt Intuitive Surgical
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]